Meropenem Steriscience (Meropenem)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the cross‑linking of peptidoglycan strands. This inhibition disrupts cell‑wall synthesis, causing osmotic instability and bacterial cell death. Its structure confers stability against most β‑lactamases, giving it a broad spectrum of activity.

The dosage of Meropenem Steriscience is individualized and determined by the prescribing clinician based on the type and severity of infection, renal function, and patient weight. Dosing regimens may range from 0.5 g to 2 g administered intravenously every 8 hours, but the exact schedule must be set by a qualified healthcare professional.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the anticipated benefit to the mother outweighs any potential risk to the fetus or infant. Breastfeeding mothers should consult their physician, as meropenem is excreted in breast milk in small amounts.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain logistics if needed), and assists with import documentation.

Meropenem offers a broad spectrum that includes many Gram‑negative, Gram‑positive, and anaerobic pathogens, and it is stable against most β‑lactamases. Compared with imipenem‑cilastatin, meropenem has a lower risk of nephrotoxicity and does not require co‑administration of a renal protective agent. It is often preferred when high‑level resistance to other β‑lactams is suspected.

Meropenem Steriscience should be stored at 2 °C to 8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake vigorously. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept refrigerated if not administered immediately.

The product is supplied for intravenous infusion. After reconstitution with the appropriate diluent, the solution is administered over 15–30 minutes, depending on the dose and clinical protocol. Infusion should be performed using aseptic technique, and the line should be flushed before and after administration to ensure complete delivery.

Serious adverse events include seizures, especially in patients with pre‑existing central nervous system disorders or when high doses are used, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and acute renal impairment. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Meropenem Steriscience is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with severe renal impairment should not receive standard doses without appropriate adjustment, and those with a history of seizure disorders should be used with caution or avoided if alternative therapies exist.